Confirmed rebound should be addressed promptly to prevent the negative consequences
of ongoing viral replication. The urgency of recall is greater for patients receiving regimens with a low genetic barrier to resistance. Every newly diagnosed patient should have an HIV-1 plasma RNA load (‘viral AZD3965 manufacturer load’) measurement taken at the time of diagnosis (Ia). In primary infection, the viral load should be monitored at presentation and again at between 3 and 6 months to establish the ‘set point’ (Ia). Patients not receiving ART who are clinically stable should undergo viral load measurements once every 6 months (IIa). The viral load should be determined within 1 month prior to initiation of therapy to confirm the pre-ART baseline value (IV). Viral load should be tested 4 weeks after commencement of treatment, when a decline in mTOR inhibitor viral load of greater than 1 log10 copies/mL relative to the pre-therapy baseline value should be observed (IIa). Further viral load measurements at 3 and 6 months are recommended to confirm full virological suppression below 50 copies/mL (Ia), taking into account that the time to undetectability is prolonged in patients monitored using new viral load assays. Subsequent viral load testing should be performed routinely every 3–4 months (Ia). In select adherent patients on well-tolerated, effective and stable regimens, 6-monthly follow-up may be considered (IIb). A viral load rebound to above 50
copies/mL should be confirmed by testing a subsequent sample (IIb). Repeat testing of the same sample is not recommended (IV). Confirmed viraemia should be addressed promptly to assess the underlying determinants and avoid accumulation of resistance (Ia). Despite the significant (-)-p-Bromotetramisole Oxalate improvements introduced in recent years, HIV sequence variability continues to challenge molecular viral load assays [1-3]. Mismatches between primers and probes and RNA target sequences could result in falsely low or undetectable viral loads in some samples. Testing with a second method is recommended when the viral load results are not consistent with the patient’s history (IIa). Based on available information, viral RNA
in blood samples collected into ethylenediaminetetraacetic acid (EDTA) tubes is stable for at least 2–3 days at room temperature, allowing transportation of the sample by post or collection over a weekend [4, 5]. If samples cannot be sent to the laboratory immediately after collection, they should be kept at room temperature (IIb). Use of plasma preparation tubes (PPT) tubes is not recommended (IIa) as they tend to produce more low-level viral load results compared with EDTA tubes [6, 7]. Current assays have similar but not identical reading levels for similar values of viraemia [8-10]. It is recommended that clinicians engage actively with local laboratory services in order to discuss the performance of the viral load assay provided and appropriately interpret its results (IV).
Related posts:
- 5%) When lopinavir fails with the emergence of the V47A mutation
- While these issues are being addressed, genomic pursuits in zebra
- To prevent PCR goods from DNA, RNA was treated with DNase and PCR
- Complete RNA extract sam ples were promptly frozen for long lasti
- Within the existing examine, we addressed regardless of whether